Anti-glycation defences in XXXX .

@entity14625 @entity45768 @entity2041 @entity2197 @entity70941 @entity66625 @entity3650 @entity375
@entity375 is an outstanding cellular model for metabolic studies in glycation. Due to its high glycolytic activity, it produces @entity14625 , a highly reactive intracellular glycation agent, at a rate of approx. 0.1% of the glycolytic flux. We investigated @entity14625 metabolism in @entity375 cells, using haploid null mutants. Growth studies showed that the most sensitive strains to @entity45768 were the null mutants for @entity66625 and @entity70941 , coding for @entity2041 synthase I and glyoxalase I respectively. The GRE3 null mutant, lacking @entity3650 reductase activity, is as sensitive as the control strain. Kinetic modelling and computer simulation of this type of experiment were also performed, and we concluded that the most important parameters for controlling the intracellular concentration of @entity14625 are the activity of glyoxalase I and the @entity2197 concentration. Moreover, our model predicts an intracellular steady-state concentration of @entity14625 of approx. 2 microM. Our results show that the glyoxalase pathway is the main detoxification pathway for @entity45768 in @entity375 , and is likely to be the key enzymatic anti-glycation agent in these cells.
